Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study

被引：0
|
作者：
Dent, S. [1 ]
Alder, L. [1 ]
Broadwater, G. [1 ]
Hyslop, T. [1 ]
Oeffinger, K. [1 ]
Khouri, M. [1 ]
Balu, S. [2 ]
Kimmick, G. [1 ]
机构：
[1] Duke Canc Inst, Cardiooncol, Durham, NC USA
[2] Novartis Pharmaceut, HEOR, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324P
引用
收藏
页码：S505 / S506
页数：2
相关论文
共 50 条
  • [1] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [2] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [3] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [4] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [6] A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i)
    Mainor, Candace Bavette
    Barrows, Elizabeth Dominic
    Wang, Hongkun
    Lynce, Filipa
    Ashai, Nadia
    Collins, Julie Marie
    Swanson, Nicole
    Castle, Julie
    Novielli, Antonella
    Slingerland, Joyce
    Isaacs, Claudine
    Pohlmann, Paula R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
    Galardi, F.
    Biagioni, C.
    De Luca, F.
    Curigliano, G.
    Minisini, A. M.
    Bonechi, M.
    Moretti, E.
    Risi, E.
    Migliaccio, I.
    McCartney, A.
    Benelli, M.
    Romagnoli, D.
    Conti, V.
    Biganzoli, L.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S18 - S18
  • [8] Therapy of advanced HR+, HER2-Breast Cancer Live professionally longer with CDK4/6 Inhibitor
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [9] Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
    Schettini, Francesco
    Palleschi, Michela
    Mannozzi, Francesca
    Braso-Maristany, Fara
    Cecconetto, Lorenzo
    Galvan, Patricia
    Mariotti, Marita
    Ferrari, Alessia
    Scarpi, Emanuela
    Miserocchi, Anna
    Nanni, Oriana
    Sanfeliu, Esther
    Prat, Aleix
    Rocca, Andrea
    De Giorgi, Ugo
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Patient & oncologist preferences for adjuvant CDK4/6i therapy in HR+/HER2-early breast cancer
    Beusterien, K.
    Law, E. H.
    Hallissey, B.
    Smith, M. L.
    Gaschler, M.
    Maculaitis, M. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S321 - S322
12345